Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
Study Details
Study Description
Brief Summary
This study is being conducted in order to assess the need for dose adjustment for elafibranor in patients with hepatic impairment. Pharmacokinetic parameters of elafibranor and its active metabolite (GFT1007) will be compared in hepatic impaired patients (mild, moderate and severe according to Child-Pugh categories) versus healthy participants after a single oral administration of elafibranor 120 mg.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Mild Child-Pugh A Single oral dose of elafibranor 120mg |
Drug: Elafibranor
120mg oral single dose
Other Names:
|
| Experimental: Moderate Child-Pugh B Single oral dose of elafibranor 120mg |
Drug: Elafibranor
120mg oral single dose
Other Names:
|
| Experimental: Severe Child-Pugh C Single oral dose of elafibranor 120mg |
Drug: Elafibranor
120mg oral single dose
Other Names:
|
| Experimental: Healthy Single oral dose of elafibranor 120mg |
Drug: Elafibranor
120mg oral single dose
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Area under curve from dosing time to last measurement (AUC(0-t)) of elafibranor and active metabolite [pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired patients]
In participants with mild, moderate and severe hepatic impairment compared to healthy volunteers
- Area under curve from dosing time to infinity (AUC(0-∞)) of elafibranor and active metabolite [pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired patients]
In participants with mild, moderate and severe hepatic impairment compared to healthy volunteers
Secondary Outcome Measures
- Plasma pharmacokinetics: maximum plasma drug concentration (Cmax) [pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants]
for elafibranor and metabolites
- Plasma pharmacokinetics: elimination half-life (t1/2) [pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants]
for elafibranor and metabolites
- Plasma pharmacokinetics: apparent volume of distribution (Vd/F) [pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants]
for elafibranor
- Plasma pharmacokinetics: renal clearance (CLr) [pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants]
for elafibranor and metabolites
- Plasma pharmacokinetics: apparent non renal clearance (CLnr/F) [pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants]
for elafibranor
- Plasma pharmacokinetics: apparent total clearance (CL/F) [pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants]
for elafibranor
- Plasma pharmacokinetics: area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total area under the plasma concentration-time curve (%AUCextra) [pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants]
for elafibranor and metabolites
- Plasma pharmacokinetics: area under curve from dosing time to last measurement (AUC(0-t)) of glucuronide metabolites and corresponding aglycones [pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants]
for the glucuronide metabolites of elafibranor and corresponding aglycones
- Plasma pharmacokinetics: area under curve from dosing time to infinity (AUC(0-∞)) of glucuronide metabolites and corresponding aglycones [pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired patients]
for the glucuronide metabolites of elafibranor and corresponding aglycones
- Urine pharmacokinetics: amount excreted (Ae) [pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose]
for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose
- Urine pharmacokinetics: cumulative amount excreted (Ae0-t) [pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose]
for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose
- Urine pharmacokinetics: percentage of dose excreted (Fe) [pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose]
for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose
- Urine pharmacokinetics: cumulative percent of dose excreted (Fe0-t) [pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose]
for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose
- Urine pharmacokinetics: renal clearance (CLR) [pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose]
for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose
Eligibility Criteria
Criteria
Inclusion Criteria:
- For all participants:
-
Males or females, between 18 and 75 years of age, inclusive;
-
With a minimum body weight of 50 kg and within a BMI range of 18.0 to 40.0 kg/m², inclusive;
-
Females participating in this study must be of non-childbearing potential or using highly efficient contraception for the full duration of the study
-
Negative serum pregnancy test at screening (if applicable);
-
Negative human immunodeficiency virus antibody screens at Screening;
- For hepatically impaired participants:
- Participants who have chronic (≥ 6 months) mild, moderate, or severe hepatic insufficiency (of any etiology) that has been clinically stable (no acute episodes of illness due to deterioration in hepatic function) for at least 1 month prior to Screening Currently on a stable medication regimen
- For healthy volunteers with normal hepatic function:
-
Non-smokers
-
Matched to participants with Mild and/or Moderate and/or Severe hepatic impairment in age (± 10 years), BMI (± 20 percent) and gender.
Other protocol-defined inclusion criteria may apply
Exclusion Criteria:
- For all participants:
-
A positive alcohol test result at Check-in;
-
A history of alcohol abuse in the prior 2 years;
-
Positive urine screen for drugs of abuse at Screening or Check-in.
-
Strenuous exercise within 72 hours prior to Check-in;
-
Blood donation or loss of blood (excluding volume drawn at screening or menses) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the dosing;
-
History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy and hernia repair will be allowed. Bariatric surgery will not be allowed.
-
Presence or history of malignancy within the prior 3 years, with the exception of treated basal cell or squamous cell carcinoma;
-
Poor peripheral venous access;
-
Receipt of blood products within 2 months prior to Check-in;
- For hepatically impaired participants:
-
History of unstable diabetes mellitus Subjects who have a transjugular intrahepatic portosystemic shunt and/or have undergone portacaval shunting;
-
Participant has shown evidence of hepatorenal syndrome or has creatinine clearance ≤ 60 mL/min Subject has required treatment for GI bleeding within the 6 months prior to Check in;
-
Recent history of paracentesis (< 3 months prior to Check-in);
-
Participants with Wilson's disease, alpha-1 antitrypsin deficiency, glycogen storage diseases, or galactosemia;
-
Participants with anemia secondary to hepatic disease, unless hemoglobin is ≥ 9 g/dL and anemia symptoms are not clinically significant. Subjects must have ≥ 35 000 platelets at screening and at Day -1;
- For healthy volunteers with normal hepatic function:
-
Significant history or clinical manifestation of any metabolic (including thyroid), allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular (including any prior history of cardiomyopathy or cardiac failure), gastrointestinal (GI), neurological, or psychiatric disorder;
-
Positive serologic test for hepatitis B surface antigen or for hepatitis C virus antibody at Screening;
-
Frequent headaches (> twice a month) and/or migraines, recurrent nausea and/or vomiting;
-
Participants with symptomatic hypotension at Screening, whatever the decrease of blood pressure, or asymptomatic postural hypotension;
-
Cholecystectomy
Other protocol-defined exclusion criteria may apply
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Division of Clinical Pharmacology, University of Miami | Miami | Florida | United States | 33136 |
| 2 | inVentiv Health Clinical Research | Miami | Florida | United States | 33136 |
Sponsors and Collaborators
- Genfit
- Syneos Health
- University of Miami
Investigators
- Study Director: Pascal BIRMAN, MD, Genfit
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GFT505-118-14